Table 1.

Anti-CCP, anti-CAP, and anti-CCP/anti-CAP ratios in patients with SLE, RA, and controls.

Diagnosis/SubsetnAnti-CCP > 1.7,%Anti-CCP > 10, %Anti-CAP > 1.7,%Anti-CCP/anti-CAP > 2.0, %Anti-CCP/anti-CAP > 2.0 (CCP > 1.7),%
Total SLE32917 (55/329)1 (4/329)18 (59/329)6 (21/329)18 (10/55)
Arthritis (SLE criteria)27117 (47/271)1 (3/271)18 (49/251)7 (19/271)19 (9/47)
I. Deforming arthropathy (Jaccoud’s)2030 (6/20)5 (1/20)30 (6/20)10 (2/20)33 (2/6)
Nondeforming/nonerosive arthritis25116 (41/251)1 (2/251)17 (43/251)7 (17/251)17 (7/41)
II. RA criteria1833 (6/18)0 (0/18)39 (7/18)0 (0/18)0 (0/6)
III. Joint swelling (+), no RA criteria3910 (4/39)3 (1/39)3 (1/39)3 (1/39)25 (1/4)
IV. Arthritis but no joint swelling19416 (31/194)1 (1/194)18 (35/194)8 (16/194)19 (6/31)
V. No arthritis5814 (8/58)2 (1/58)17 (10/58)3 (2/58)13 (1/8)
Japanese with SLE with deforming/erosive arthritis667 (4/6)33 (2/6)17 (1/6)50 (3/6)75 (3/4)
RA476826937791
Control3590111767
  • CCP: citric citrullinated peptide; CAP: cyclic arginine peptide.